---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-039514"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:01:38.796039+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anteris enrolls & treats first patients in DurAVR THV global pivotal trial

## Summary
- First patients enrolled and successfully treated in PARADIGM Trial for DurAVR THV in severe calcific aortic stenosis.
- Procedure performed by Prof. Dr. Ole De Backer at Rigshospitalet, Copenhagen University Hospital, Denmark.
- Trial is a randomized controlled study (1:1 vs commercial TAVRs) enrolling ~1,000 patients in All Comers Cohort.
- Primary endpoint: all-cause mortality, all stroke, cardiovascular hospitalization at one year post procedure.
- Expands existing data set of 130 patients; plans to add sites across US, Europe, and Canada.

## SEC filing metadata
- accession: 0001140361-25-039514
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125039514/0001140361-25-039514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125039514/ef20057756_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-039514
- JSON: https://secwatch.observer/filing/0001140361-25-039514.json
- Plain text: https://secwatch.observer/filing/0001140361-25-039514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.